Unknown PHASE2 INTERVENTIONAL 2-arm NCT01461512

Heme Arginate in Functional Magnetic Resonance Imaging (fMRI)

The Effects of Intravenous Heme Arginate on Functional Magnetic Resonance Imaging During Ischemia

Sponsor: MWolzt

Interventions Placebo administration heme arginate administration

Updated 5 times since 2017 Last updated: Oct 26, 2011 Started: Jan 31, 2009 Primary completion: Aug 31, 2011 Completion: Dec 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01461512, this PHASE2 trial focuses on Ischemia-reperfusion Injury and remains ongoing. Sponsored by MWolzt, it has been updated 5 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MWolzt

Data source: Medical University of Vienna

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Vienna, Austria